Sandifer Syndrome Medication
- Author: Pegeen Eslami, MD; Chief Editor: Carmen Cuffari, MD more...
Therapeutic response for the treatment of gastroesophageal reflux disease may take several weeks. If treatment is successful, the frequency of posturing and apparent distress will decrease.
These agents are used to augment cholinergic activity. As such, they can improve contractility of the lower esophagus, increase lower esophageal sphincter pressure and augment the rate of gastric emptying. However these agents have a limited role in this age group as the risk of adverse side effects generally outweighs benefit. Current guidelines do not support the routine use of prokinetic agents for the treatment of GERD in infants or older children.[12, 17] Use of PPIs should be considered only in specific situation with thorough consideration of risks and benefit.
Dopaminergic antagonist that works by increasing LES tone and gastric emptying. Stimulates muscular activity, leading to decrease in reflux.
These agents have traditionally been used as a diagnostic tool, providing symptomatic relief in infants. However, although they may confer short term relief, they are not recommended for long-term use due to the risk of associated aluminum toxicity and/or milk-alkali syndrome. They are not currently recommended for the treatment of GERD in infants and children.[14, 20]
Increases gastric pH above 4 and inhibits proteolytic activity of pepsin, reducing acid indigestion. Antacids can initially be used in mild cases. No effect on frequency of reflux but decreases its acidity.
Causes osmotic retention of fluid, which distends colon and increases peristaltic activity. Forms magnesium chloride in vivo after reacting with stomach hydrochloric acid.
H2 receptor antagonists
Like antacids, these agents do not reduce the frequency of reflux, but they are very effective in decreasing the amount of acid in the refluxate through inhibition of acid production by blocking the histamine H2 receptors on gastric parietal cells. All are equipotent when used in equivalent doses. Long- term use is limited by the development of tachyphylaxis or tolerance. These medications are very useful for short term trial of acid suppression.
Inhibits histamine stimulation of the H2 receptor in gastric parietal cells, which reduces gastric acid secretion, gastric volume, and hydrogen ion concentrations.
Competitively inhibits histamine at H2 receptor of gastric parietal cells, resulting in reduced gastric acid secretion, gastric volume, and hydrogen ion concentrations.
Nizatidine is approved by the FDA for use in adolescents aged 12-18 y. Off-label use in children younger than 12 y has been described.
Proton pump inhibitors
Proton pump inhibitors (PPIs) decrease acid secretion by irreversibly binding to and inhibiting the H+-K+-ATPase pump on the gastric parietal cell surface. They are more effective at increasing gastric pH, and for a longer duration, compared with H2 receptor antagonists (H2RA). Additionally, they do not cause the tolerance seen after several weeks use of the H2RAs. As a result, PPIs contribute to more rapid healing of erosive esophagitis. There is mixed evidence as to their efficacy in reducing irritability in infants.[15, 22] Concerns exist regarding overuse and over prescribing of PPIs, and the long-term adverse effects (eg, increased in respiratory infections in infants, headache, nausea, diarrhea and constipation in older children and adults).[12, 20]
Omeprazole, lansoprazole, pantoprazole and esomeprazole have all been studied in infants and young children. Currently, the only PPI approved by the FDA for use in infants aged 1-12 months is esomeprazole.
Decreases gastric acid secretion by inhibiting the parietal cell H+-K+-ATP pump.
Suppresses gastric acid secretion by specific inhibition of the (H+, K+)-ATPase enzyme system (ie, proton pump) at the secretory surface of the gastric parietal cell. It blocks the final step of acid production. The effect is dose-related and inhibits both basal and stimulated gastric acid secretion, thus increasing gastric pH.
S-isomer of omeprazole. Inhibits gastric acid secretion by inhibiting H+-K+-ATPase enzyme system at secretory surface of gastric parietal cells.
Frankel EA, Shalaby TM, Orenstein SR. Sandifer syndrome posturing: relation to abdominal wall contractions, gastroesophageal reflux, and fundoplication. Dig Dis Sci. 2006 Apr. 51(4):635-40. [Medline].
Kirkham FJ, Haywood P, Kashyape P, Borbone J, Lording A, Pryde K, et al. Movement disorder emergencies in childhood. Eur J Paediatr Neurol. 2011 Sep. 15(5):390-404. [Medline].
Obeid M, Mikati MA. Expanding spectrum of paroxysmal events in children: potential mimickers of epilepsy. Pediatr Neurol. 2007 Nov. 37(5):309-16. [Medline].
Kostakis A, Manjunatha NP, Kumar A, Moreland ES. Abnormal head posture in a patient with normal ocular motility: Sandifer syndrome. J Pediatr Ophthalmol Strabismus. 2008 Jan-Feb. 45(1):57-8. [Medline].
Lehwald N, Krausch M, Franke C, Assmann B, Adam R, Knoefel WT. Sandifer syndrome--a multidisciplinary diagnostic and therapeutic challenge. Eur J Pediatr Surg. 2007 Jun. 17(3):203-6. [Medline].
Kabakus N, Kurt A. Sandifer Syndrome: a continuing problem of misdiagnosis. Pediatr Int. 2006 Dec. 48(6):622-5. [Medline].
Shepherd RW, Wren J, Evans S, et al. Gastroesophageal reflux in children. Clinical profile, course and outcome with active therapy in 126 cases. Clin Pediatr (Phila). 1987 Feb. 26(2):55-60. [Medline].
Nalbantoglu B, Metin DM, Nalbantoglu, A. Sandifer's Syndrome: A Misdiagnosed and Mysterious Disorder. Iran Journal of Pediatrics. December 2013. 23 (6):715-716.
Deskin RW. Sandifer syndrome: a cause of torticollis in infancy. Int J Pediatr Otorhinolaryngol. 1995 May. 32(2):183-5. [Medline].
Orenstein SR. Update on gastroesophageal reflux and respiratory disease in children. Can J Gastroenterol. 2000 Feb. 14(2):131-5. [Medline].
Del Giudice E, Staiano A, Capano G, et al. Gastrointestinal manifestations in children with cerebral palsy. Brain Dev. 1999 Jul. 21(5):307-11. [Medline].
Vandenplas Y, Rudolph CD, Di Lorenzo C et al. Pediatric Gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology Hepatology and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN). Journal of Pediatric Gastroenterology and Nutrition. 2009. 49 (4):498-547.
Ward RM, Kearns GL. Proton Pump Inhibitors in Pediatrics: Mechanism of Action, Pharmacokinetcis, Phamacogenetics, and Pharmacodynamics. Pediatric Drugs. March 2013. 15 (2):119-131.
Tighe M, Afzal NA, Bevan A, Munro A, Beattie RM. Pharmacologic treatment of children with gastroesophageal reflux (Review). The Cochrane Collaboration. 2014. Issue 11:1-83. [Full Text].
van der Pol RJ, Smits MJ, van Wijk MP et al. Efficacy of Proton-Pump Inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics. 2011. 127 (5):925.
Orenstein SR, Hassall E, Furmaga-Jablonska W et al. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. Journal of Pediatrics. 2009. 154 (4):514.
Craig WR, Hanlon-Dearmane A, Sinclair C et al. Metoclopramide, thickened feedings and positioning for gastro-esophageal reflux in children under 2 years. Cochrane Database Systematic Reviews. 2004. [Medline].
Horvath A, Dziechciarz P, Szajewska H. The effect of thickened-feed interventions of gastroesophageal reflux in infants: systematic review and meta-analysis of randomized, controlled trials. Pediatrics. 2008. 122 (6):e1268. [Medline].
Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008 Oct. 135(4):1383-1391, 1391.e1-5. [Medline].
Lightdale JR, Gremse DA, Section on Gastroenterology, Hepatology, and Nutrition. Gastroesophageal reflux: management guidance for the pediatrician. Pediatrics. 2013 May. 131 (5):e1684-95. [Medline].
Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997 Jun. 112 (6):1798-810. [Medline].
Moore DJ, Tao BS, Lines DR, Hirte C, Heddle ML, Davidson GP. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr. 2003 Aug. 143 (2):219-23. [Medline].
Bamji N, Berezin S, Bostwick H, Medow MS. Treatment of Sandifer Syndrome with an Amino-Acid-Based Formula. AJP Rep. 2015 Apr. 5 (1):e51-2. [Medline].
Dias E, Ramachandra C, D'Cruz AJ, Yeshwanth M. An unusual presentation of gastro-oesophageal reflux--Sandifer's syndrome. Trop Doct. 1992 Jul. 22(3):131. [Medline].
Gold BD. Gastroesophageal reflux disease: could intervention in childhood reduce the risk of later complications?. Am J Med. 2004 Sep 6. 117 Suppl 5A:23S-29S. [Medline].
Gorrotxategi P, Reguilon MJ, Arana J. Gastroesophageal reflux in association with the Sandifer syndrome. Eur J Pediatr Surg. 1995 Aug. 5(4):203-5. [Medline].
Mandel H, Tirosh E, Berant M. Sandifer syndrome reconsidered. Acta Paediatr Scand. 1989 Sep. 78(5):797-9. [Medline].
Somjit S, Lee Y, Berkovic SF, Harvey AS. Sandifer syndrome misdiagnosed as refractory partial seizures in an adult. Epileptic Disord. 2004 Mar. 6(1):49-50. [Medline].
Theodoropoulos DS, Flockey RF, Boyce HW Jr. Sandifer's syndrome and gastro-oesophageal reflux disease. J Neurol Neurosurg Psychiatry. 1999 Jun. 66(6):805-6. [Medline].
Werlin SL, D'Souza BJ, Hogan WJ, Dodds WJ, Arndorfer RC. Sandifer syndrome: an unappreciated clinical entity. Dev Med Child Neurol. 1980 Jun. 22(3):374-8. [Medline].
Werlin SL, Dodds WJ, Hogan WJ, Arndorfer RC. Mechanisms of gastroesophageal reflux in children. J Pediatr. 1980 Aug. 97(2):244-9. [Medline].